期刊
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
卷 72, 期 -, 页码 93-105出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-080119-103356
关键词
functional cure; chronic viral hepatitis; HBV surface antigen; curative therapy; targeted antivirals
Chronic hepatitis B virus infection affects an estimated 257-291 million people globally, with current treatment approaches being complex and lacking in durable effects, leading to low uptake rates. Multiple targeted therapies are being studied to achieve persistent HBV suppression within a finite period of treatment.
Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable treatment response, necessitating indefinite treatment in the majority of cases, have resulted in low uptake of testing and treatment, particularly in regions where comprehensive primary care is lacking and access to affordable testing and treatment is limited. Multiple targeted therapies are now in early human study with the primary goal to achieve persistent HBV DNA and hepatitis B surface antigen suppression after a finite course of treatment, which is referred to as functional cure. This article summarizes the current therapies for HBV infection and discusses the limitations of these therapies, novel approaches to HBV cure, and therapeutic endpoints of clinical trials aimed to cure hepatitis B.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据